[Successful treatment of refractory anemia with excess of blasts in transformation with cytarabine ocfosfate].

A 58-year-old female was diagnosed as myelodysplastic syndrome (MDS) [refractory anemia with excess of blasts (RAEB)]. Although melphalan was administered, no response was obtained in the peripheral blood. Sixteen months after diagnosis, she developed RAEB in transformation (RAEB-t), and then overt leukemia. White blood cell (WBC) count elevated to 28,600/microliters with 34% of blasts. She was administered cytarabine ocfosfate (200 mg-->300 mg/day) orally, resulting in decrease of WBC count and blasts in peripheral blood. The drug has been given for 11 months, and her hematological data have now remained stable in RAEB. Cytarabine ocfosfate might be a useful drug for the treatment of high risk MDS such as RAEB and RAEB-t.
AuthorsM Takeuchi, K Kojima, S Takaba, M Isokawa, M Tanimizu, F Kimura, E Ohmoto, M Harada
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 22 Issue 1 Pg. 141-4 (Jan 1995) ISSN: 0385-0684 [Print] JAPAN
PMID7826071 (Publication Type: Case Reports, English Abstract, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Arabinonucleotides
  • 1-arabinofuranosylcytosine-5'-stearylphosphate
  • Cytidine Monophosphate
  • Acute Disease
  • Administration, Oral
  • Anemia, Refractory, with Excess of Blasts (drug therapy, pathology)
  • Antineoplastic Agents (administration & dosage)
  • Arabinonucleotides (administration & dosage)
  • Cytidine Monophosphate (administration & dosage, analogs & derivatives)
  • Female
  • Humans
  • Leukemia (pathology)
  • Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: